Bio-Path Holdings
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® neutral-charge liposomal delivery platform, with drug candidates in Phase 1 and Phase 2 trials for AML, lymphoma, and solid tumors.
- Company typePublic
- Founded2008
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bio-Path Holdings does
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform. The platform combines a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes to deliver antisense DNA directly to cancer cells, a chemistry the company says avoids the dose-limiting toxicities of positively-charged lipid delivery systems. The company was founded in 2008 around technology licensed from The University of Texas MD Anderson Cancer Center and is headquartered in Pittsburgh, Pennsylvania, with prior external references placing it in Bellaire, Texas; it has been listed on NASDAQ Capital Market under ticker BPTH since 2014.
The pipeline consists of four core candidates: prexigebersen (BP1001), a liposomal Grb2 antisense in Phase 2 for acute myeloid leukemia (AML), including combination studies with venetoclax and decitabine; BP1001-A, a reformulation for advanced solid tumors (ovarian, endometrial, pancreatic) in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense in Phase 1 for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and venetoclax-resistant AML; and BP1003, a liposomal STAT3-targeting agent in IND-enabling studies for pancreatic adenocarcinoma. Prexigebersen has received Orphan Drug Designation from both the FDA (2015) and the EMA (2016). The company has 1-10 employees, has undergone three reverse stock splits since 2018, is reincorporating from Delaware to Wyoming in 2026, and installed Vikram Grover as Chairman and CEO in October 2025 with a turnaround mandate. Institutional ownership is reported at approximately 5.7%, well below the 32.4% industry average.
Commercially, Bio-Path is pre-revenue and generates no product or licensing income. Its business model is to advance candidates through clinical trials toward regulatory approval, with future revenue expected from direct commercialization or licensing of approved drugs. Operations are funded through periodic small dilutive equity raises, with roughly $9.2M raised across three 2024 private placements and registered direct offerings and an additional ~$2M raised in November 2022; a Regulation A offering is in preparation under the new leadership.
Bio-Path Holdings firmographics
Firmographics- Name
- Bio-Path Holdings
- Legal name
- Bio-Path Holdings, Inc.
- Website
- https://biopathholdings.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® neutral-charge liposomal delivery platform, with drug candidates in Phase 1 and Phase 2 trials for AML, lymphoma, and solid tumors.
- Ownership category
- akta.pro rank
Bio-Path Holdings industry classification
Industry- Product category
- Biopharmaceuticals / Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where Bio-Path Holdings is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Bio-Path Holdings business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Drug Development and Commercialization: Bio-Path Holdings is a pre-revenue clinical-stage biotechnology company. The company does not currently generate commercial revenue. Future revenue will come from sales of approved drug products (prexigebersen, BP1001-A, BP1002, BP1003) if they receive regulatory approval, or from licensing/partnership deals with pharmaceutical companies for co-development or commercialization rights.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Bio-Path Holdings product offering
Product offeringCore offering
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform, a neutral-charge liposome-based antisense DNA delivery system. The company is advancing a pipeline of four drug candidates—prexigebersen (BP1001), BP1001-A, BP1002, and BP1003—through Phase 1 and Phase 2 clinical trials for hematologic malignancies and solid tumors. The therapeutics are designed to inhibit specific cancer-driving proteins (Grb2, Bcl-2, STAT3) and are targeted primarily at elderly or fragile patients ineligible for high-dose chemotherapy.
Product overview
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted cancer therapies leveraging its proprietary DNAbilize® platform technology for antisense DNA therapeutics delivery. The company's product portfolio consists of four main drug candidates in various clinical stages: Prexigebersen (BP1001), a liposomal Grb2 antisense for acute myeloid leukemia currently in Phase 2; BP1001-A, a modified formulation for solid tumors in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense for lymphoma and AML in Phase 1; and BP1003, a liposomal STAT3 targeting pancreatic cancer in IND-enabling studies. The DNAbilize® platform underlies all products, enabling delivery of antisense DNA through neutral-charge liposome technology that addresses traditional limitations of lipid-based delivery systems.
Differentiator
Problem solved
Functional benefit
Products and services
- Prexigebersen (BP1001) Liposomal Grb2 antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2 (Grb2), essential in cancer progression via the RAS activation pathway. Currently in Phase 2 trials for acute myeloid leukemia (AML), including combination therapies with venetoclax and decitabine, targeted at elderly and fragile AML patients.
- BP1001-A Modified formulation of prexigebersen incorporating the same Grb2 antisense drug substance with slightly modified nanoparticle properties designed to enhance delivery to solid tumors. Being evaluated in Phase 1 trials for advanced solid tumors including ovarian, endometrial, and pancreatic cancers, and in preclinical studies for obesity.
- BP1002 (Liposomal Bcl-2) Neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Bcl-2, a protein involved in blocking programmed cell death. Being evaluated in Phase 1 trials for Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and AML patients who have relapsed from venetoclax-based treatment.
- BP1003 (Liposomal STAT3) RNAi nanoparticle containing antisense DNA targeting STAT3, a protein associated with increased pancreatic adenocarcinoma severity and poorer survival. IND-enabling studies ongoing for pancreatic cancer with potential applications in non-small cell lung cancer and AML.
- DNAbilize® Platform Technology Patented neutral-charge liposome-based antisense DNA delivery system combining a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes, enabling systemic delivery of antisense therapeutics to cancer cells without dose-limiting toxicities associated with positively-charged lipid technologies.
Quantifiable outcome
- Phase 2 combination trial: 3 of 6 evaluable patients achieved complete remission, 2 achieved stable disease
- +3 more outcomes
Companies that use Bio-Path Holdings
Customer profileSegments1 record
Ideal customer profiles3 records
Bio-Path Holdings technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bio-Path Holdings partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered secondary and core.
- Thomas Jefferson UniversitysecondaryCollaboration for systemic antisense immunotherapy treatment for brain cancer using Bio-Path's liposomal delivery technology. This partnership expands the application of the DNAbilize® platform beyond blood cancers into solid tumors of the central nervous system.
- The University of Texas Southwestern Medical CentersecondaryResearch collaboration on autoimmune indication using Bio-Path's antisense delivery technology. This collaboration represents expansion of the platform technology into non-oncology therapeutic areas.
- MD Anderson Cancer Center (Pancreatic Cancer Research)secondaryPancreatic cancer research collaboration with leading oncology institution to advance BP1003 (Liposomal STAT3) for pancreatic adenocarcinoma treatment.
- The University of Texas MD Anderson Cancer CentercoreFoundational technology licensing agreement for the DNAbilize® platform technology from MD Anderson Cancer Center. The company was founded on this foundational technology and maintains a strong ongoing relationship with the Cancer Center for continued research collaboration and development of liposomal antisense therapeutics.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Bio-Path Holdings competitors and assessment
Company assessmentDirect peers
- Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide therapeutics company, with a mature pipeline including hematology and oncology programs. Directly comparable as both companies develop antisense-based nucleic acid therapeutics for cancer and rare diseases, and Ionis represents the gold-standard commercialization path Bio-Path aspires to.
- Regulus Therapeutics: Regulus develops microRNA-targeted therapeutics, with clinical programs in kidney disease and oncology. Comparable as a small-cap clinical-stage company developing nucleic acid-based therapeutics (microRNA antisense) with similar pre-revenue, partnership-dependent business model.
- Sirnaomics: Sirnaomics develops RNAi-based therapeutics using its PNP (polymeric nanoparticle) delivery platform for oncology and fibrosis. Comparable as a clinical-stage RNAi therapeutics company using nanoparticle delivery technology to target cancer indications.
- ProQR Therapeutics: ProQR develops RNA-based therapeutics (Axiomer® RNA editing platform) for rare genetic diseases. Comparable as a small-cap clinical-stage RNA/nucleic acid therapeutics company targeting diseases with high unmet need, with similar pre-commercial risk profile.
- Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra) and a lipid nanoparticle delivery platform. Comparable as a nucleic acid-based therapeutics developer using lipid-based delivery, though at vastly larger scale and commercial stage.
- Arbutus Biopharma: Arbutus develops RNAi therapeutics delivered via lipid nanoparticles (LNP) and oral delivery technology for HBV and oncology. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using lipid-based delivery — a closely adjacent technology paradigm to DNAbilize®.
- Wave Life Sciences: Wave is a clinical-stage antisense oligonucleotide company developing stereopure nucleic acid therapeutics for rare and neurological diseases. Directly comparable as a small-cap clinical-stage antisense platform company with similar pre-revenue / clinical-development profile.
Emerging players
- Cogent Biosciences: Cogent Biosciences is a clinical-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Comparable as a small-cap, clinical-stage, publicly traded oncology biotech with similar capital-raising dynamics and institutional ownership profile.
- Benitec Biopharma: Benitec uses DNA-directed RNA interference (ddRNAi) to silence disease-causing genes, with oncology and infectious disease programs. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using DNA-based mechanisms, with overlapping oncology indications.
- Geron Corporation: Geron is a small-cap clinical-to-commercial stage oncology company developing telomerase inhibitor (imetelstat) for hematologic malignancies including AML and MDS. Comparable as a small-cap oncology company targeting AML with a single platform-derived asset, facing similar commercialization and capital risks.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
Bio-Path Holdings social profiles
Digital presenceBio-Path Holdings compliance and trust
Trust signalCompliance2 records
Bio-Path Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bio-Path Holdings leadership team
Management profileNumber of profiles
Profiles7 records
Bio-Path Holdings funding detail
Funding detailFunding overview
Funding rounds13 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bio-Path Holdings M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bio-Path Holdings
What does Bio-Path Holdings do?
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform, a neutral-charge liposome-based antisense DNA delivery system. The company is advancing a pipeline of four drug candidates—prexigebersen (BP1001), BP1001-A, BP1002, and BP1003—through Phase 1 and Phase 2 clinical trials for hematologic malignancies and solid tumors. The therapeutics are designed to inhibit specific cancer-driving proteins (Grb2, Bcl-2, STAT3) and are targeted primarily at elderly or fragile patients ineligible for high-dose chemotherapy.
Is Bio-Path Holdings a public or private company?
Bio-Path Holdings is a public company. It is classified as public and is currently operating.
When was Bio-Path Holdings founded?
Bio-Path Holdings was founded in 2008. It employs 1 to 10 people.
Where is Bio-Path Holdings based?
Bio-Path Holdings is headquartered in Houston, United States, in the North America region.
How does Bio-Path Holdings make money?
One revenue line is on record: drug Development and Commercialization.
Who are Bio-Path Holdings's main competitors?
Direct peers on record are Ionis Pharmaceuticals, Regulus Therapeutics, Sirnaomics, ProQR Therapeutics, Alnylam Pharmaceuticals, Arbutus Biopharma and Wave Life Sciences. Emerging players are Cogent Biosciences, Benitec Biopharma and Geron Corporation.
Does Bio-Path Holdings have an API?
No public API is recorded for Bio-Path Holdings.
What industry is Bio-Path Holdings in?
Bio-Path Holdings's product category is Biopharmaceuticals / Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.